Penserra Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-220,858
| Closed | -$280K | – | 1393 |
|
|
2023
Q3 | $280K | Hold |
220,858
| – | – | 0.01% | 659 |
|
|
2023
Q2 | $71K | Buy |
220,858
+1,712
| +0.8% | +$614 | ﹤0.01% | 1002 |
|
|
2023
Q1 | $94K | Buy |
219,146
+3,424
| +2% | +$1.8K | ﹤0.01% | 779 |
|
|
2022
Q4 | $114K | Buy |
215,722
+3,424
| +2% | +$2.17K | ﹤0.01% | 788 |
|
|
2022
Q3 | $155K | Sell |
212,298
-137,038
| -39% | -$155K | ﹤0.01% | 682 |
|
|
2022
Q2 | $398K | Sell |
349,336
-1,818
| -0.5% | -$2.31K | 0.01% | 501 |
|
|
2022
Q1 | $719K | Sell |
351,154
-58,908
| -14% | -$140K | 0.02% | 443 |
|
|
2021
Q4 | $1.18M | Buy |
410,062
+29,364
| +8% | +$109K | 0.03% | 414 |
|
|
2021
Q3 | $1.61M | Buy |
380,698
+8,314
| +2% | +$37.1K | 0.03% | 369 |
|
|
2021
Q2 | $1.97M | Buy |
372,384
+15,508
| +4% | +$74.6K | 0.04% | 340 |
|
|
2021
Q1 | $1.66M | Buy |
356,876
+227,624
| +176% | +$1.03M | 0.03% | 316 |
|
|
2020
Q4 | $425K | Buy |
129,252
+64,250
| +99% | +$244K | 0.01% | 391 |
|
|
2020
Q3 | $214K | Sell |
65,002
-29,960
| -32% | -$110K | 0.01% | 430 |
|
|
2020
Q2 | $319K | Buy |
94,962
+7,020
| +8% | +$33.2K | 0.02% | 425 |
|
|
2020
Q1 | $336K | Buy |
87,942
+62,814
| +250% | +$292K | 0.02% | 379 |
|
|
2019
Q4 | $125K | Buy |
25,128
+6,402
| +34% | +$43.8K | 0.01% | 538 |
|
|
2019
Q3 | $141K | Buy |
+18,726
| New | +$211K | 0.01% | 457 |
|
Penserra Capital Management's ZYNE Position: Q4 2023 in Review
Penserra Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 220,858 shares — an estimated $280K sold.
Penserra Capital Management first reported a position in ZYNE in Q3 2019 and held it in 17 quarters. The position peaked at $1.97M in Q2 2021. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Penserra Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Penserra Capital Management sold 220,858 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $280K.
- Penserra Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2019 and held it in 17 quarters.
- Penserra Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $1.97M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.